Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
It is a triple agonist, targeting GLP-1, GIP, and glucagon receptors simultaneously
Unlike many peptides that have only injectable research data, GHK-Cu has been tested in published human clinical trials specifically as a topical application with outcomes that compared favorably against gold-standard actives
It helps the body produce insulin more effectively and controls blood sugar levels while also reducing appetite, often leading to weight loss
Adoption remained modest until recent years as GLP-1 drug claims rose from 6.9 percent in 2023 to 10.5 percent in 2025
TrumpRx is expected by December 2025, with full integration by Medicare in mid-2026
Whether or not you end up taking a GLP-1 medication, the broader point stands
